malignant pleural effusion
Conditions
Brief summary
The primary endpoint is progression-free survival. The comparison will be performed between the treatment group (HITHOC, n = 32) and the control group (chemical pleurodesis or indwelling pleural catheter placement, n = 32).
Detailed description
Comparison of quality of life, Comparison of overall survival, Comparison of progression-free survival in patients with isolated parietal pleural disease undergoing HITHOC plus pleurectomy versus HITHOC alone through a second randomization, Assessment of the accuracy and prognostic correlation of the intraoperative pleural disease dissemination score. This endpoint will be measured in all the patientsi
Interventions
Sponsors
Universita' Degli Studi Di Torino
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is progression-free survival. The comparison will be performed between the treatment group (HITHOC, n = 32) and the control group (chemical pleurodesis or indwelling pleural catheter placement, n = 32). | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of quality of life, Comparison of overall survival, Comparison of progression-free survival in patients with isolated parietal pleural disease undergoing HITHOC plus pleurectomy versus HITHOC alone through a second randomization, Assessment of the accuracy and prognostic correlation of the intraoperative pleural disease dissemination score. This endpoint will be measured in all the patientsi | — |
Outcome results
None listed